Single photon emission tomography assessment of cerebral dopamine D2 receptor blockade in schizophrenia.
Geaney
D P
DP
University of Oxford Department of Psychiatry, Warneford Hospital, England.
Ellis
P M
PM
Soper
N
N
Shepstone
B J
BJ
Cowen
P J
PJ
D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001479:Basal Ganglia / Q000000981:diagnostic imaging / Q000187:drug effects; D001549:Benzamides / Q000493:pharmacokinetics; D001921:Brain / Q000000981:diagnostic imaging / Q000187:drug effects*; D002531:Cerebellum / Q000000981:diagnostic imaging / Q000187:drug effects; D003287:Contrast Media; D006801:Humans; D007457:Iodine Radioisotopes; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D011759:Pyrrolidines / Q000493:pharmacokinetics; D017448:Receptors, Dopamine D2 / Q000187:drug effects*; D012559:Schizophrenia / Q000000981:diagnostic imaging / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D015899:Tomography, Emission-Computed, Single-Photon
D014150:Antipsychotic Agents; D001549:Benzamides; D003287:Contrast Media; D007457:Iodine Radioisotopes; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide